5 years of successful inducible transgene expression following locoregional AAV delivery in nonhuman primates with no detectable immunity
Self archived versionfinal draft
MetadataShow full item record
CitationGuilbaud, Mickaël. Devaux, Marie. Couzinié, Celia. Le Duff, Johanne. Toromanoff, Alice. Vandamme, Céline. Jaulin, Nicolas. Gernoux, Gwladys. Larcher, Thibaut. Moullier, Philippe. Le Guiner, Caroline. Adjali, Oumeya. (2019). 5 years of successful inducible transgene expression following locoregional AAV delivery in nonhuman primates with no detectable immunity. Human gene therapy, Published Online 27 Feb 2019, 10.1089/hum.2018.234.
Anti-transgene immune responses elicited after intramuscular (i.m.) delivery of recombinant adeno-associated virus (rAAV) have been shown to hamper long-term transgene expression in large-animal models of rAAV-mediated gene transfer. To overcome this hurdle, an alternative mode of delivery of rAAV vectors in nonhuman primate muscles has been described: the locoregional (LR) intravenous route of administration. Using this injection mode, persistent inducible transgene expression for at least 1 year under the control of the tetracycline-inducible Tet-On system was previously reported in cynomolgus monkeys, with no immunity against the rtTA transgene product. The present study shows the long-term follow-up of these animals. It is reported that LR delivery of a rAAV2/1 vector allows long-term inducible expression up to at least 5 years post gene transfer, with no any detectable host immune response against the transactivator rtTA, despite its immunogenicity following i.m. gene transfer. This study shows for the first time a long-term regulation of muscle gene expression using a Tet-On-inducible system in a large-animal model. Moreover, these findings further confirm that the rAAV LR delivery route is efficient and immunologically safe, allowing long-term skeletal muscle gene transfer.